High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study
Background The IL-6R antibody tocilizumab has been proven effective in treating Takayasu arteritis (TA). However, some patients show silent vascular stenosis progression (VSP) despite treatment with tocilizumab. The aim of the study was to explore the related risk factors of VSP in patients treated with tocilizumab. Methods Patients receiving tocilizumab were enrolled from the prospective living ongoing East China Takayasu Arteritis cohort. Their medical information was uniformly recorded with a homogenized evaluation method. Magnetic resonant angiography or computed tomographic angiography was employed to monitor VSP during the follow-up period, and Cox regression analysis was performed to explore the related risk factors. Results Thirty-eight patients were enrolled, among whom 18 (47.4%) experienced VSP, and seven and three patients experienced new and worsened vascular ischemic symptoms and events (VISE) during follow-up, respectively. The median period for VSP occurrence was 6.9 months during follow-up. Patients with VSP showed higher levels of baseline complement 3 (C3) than those in the patients without VSP. Multivariate Cox regression analysis revealed baseline C3 level (hazard ratio [HR] = 7.05, 95% confidence interval: 1.50–33.07, p = 0.013) was independently associated with VSP, with a cut-off value of 1.22 g/L. Conclusions 47.4% of TA patients treated with tocilizumab would suffer VSP. A high C3 level is a risk factor for VSP in TA patients receiving tocilizumab, which may facilitate the option of tocilizumab in the future..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Arthritis Research & Therapy - 25(2023), 1 vom: 02. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rongyi, Chen [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Complement 3 |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s13075-023-03106-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052619451 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052619451 | ||
| 003 | DE-627 | ||
| 005 | 20230803064711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230803s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13075-023-03106-7 |2 doi | |
| 035 | |a (DE-627)SPR052619451 | ||
| 035 | |a (SPR)s13075-023-03106-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rongyi, Chen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background The IL-6R antibody tocilizumab has been proven effective in treating Takayasu arteritis (TA). However, some patients show silent vascular stenosis progression (VSP) despite treatment with tocilizumab. The aim of the study was to explore the related risk factors of VSP in patients treated with tocilizumab. Methods Patients receiving tocilizumab were enrolled from the prospective living ongoing East China Takayasu Arteritis cohort. Their medical information was uniformly recorded with a homogenized evaluation method. Magnetic resonant angiography or computed tomographic angiography was employed to monitor VSP during the follow-up period, and Cox regression analysis was performed to explore the related risk factors. Results Thirty-eight patients were enrolled, among whom 18 (47.4%) experienced VSP, and seven and three patients experienced new and worsened vascular ischemic symptoms and events (VISE) during follow-up, respectively. The median period for VSP occurrence was 6.9 months during follow-up. Patients with VSP showed higher levels of baseline complement 3 (C3) than those in the patients without VSP. Multivariate Cox regression analysis revealed baseline C3 level (hazard ratio [HR] = 7.05, 95% confidence interval: 1.50–33.07, p = 0.013) was independently associated with VSP, with a cut-off value of 1.22 g/L. Conclusions 47.4% of TA patients treated with tocilizumab would suffer VSP. A high C3 level is a risk factor for VSP in TA patients receiving tocilizumab, which may facilitate the option of tocilizumab in the future. | ||
| 650 | 4 | |a Takayasu arteritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tocilizumab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Vascular stenosis progression |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Complement 3 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Xiaojuan, Dai |4 aut | |
| 700 | 1 | |a Jinghua, Wang |4 aut | |
| 700 | 1 | |a Lingying, Ma |4 aut | |
| 700 | 1 | |a Xiaomin, Dai |4 aut | |
| 700 | 1 | |a Lili, Ma |4 aut | |
| 700 | 1 | |a Huiyong, Chen |4 aut | |
| 700 | 1 | |a Lindi, Jiang |4 aut | |
| 700 | 1 | |a Ying, Sun |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis Research & Therapy |d London : BioMed Central, 1999 |g 25(2023), 1 vom: 02. Aug. |w (DE-627)SPR030212995 |w (DE-600)2041668-4 |x 1478-6354 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:1 |g day:02 |g month:08 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13075-023-03106-7 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 1 |b 02 |c 08 | ||